|
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation. |
|
|
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst) |
Travel, Accommodations, Expenses - Polaris |
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Baxalta; Delcath Systems; Ipsen; Lilly; Merck; Midatech Pharma; Novartis; Pfizer |
Speakers' Bureau - Celgene; Novartis; Pfizer |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Lilly; Novartis |
|
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst) |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst) |
|
|
Honoraria - Ribon Therapeutics |
Research Funding - Dicerna; Exelixis; Leap Therapeutics; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme |
Research Funding - Agios; Celgene; Lilly |
Travel, Accommodations, Expenses - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline |
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2 |
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun BioPharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst) |
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene |
|
|
|
|
Travel, Accommodations, Expenses - Agios; Roche |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CytomX Therapeutics |
Speakers' Bureau - Merrimack |
|
|
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Delcath Systems; Lilly; MSD; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Baxalta; Bayer; Delcath Systems; Lilly; Novartis; Roche |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche |
|
|
|
Stock and Other Ownership Interests - Agios |
|
|
|
Stock and Other Ownership Interests - Alexion Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Agios |
|
|
|
Stock and Other Ownership Interests - Agios |
Patents, Royalties, Other Intellectual Property - Agios |
|
|
|
Stock and Other Ownership Interests - Agios |
Patents, Royalties, Other Intellectual Property - Agios |
|
|
Employment - Acceleron Pharma; Agios |
Stock and Other Ownership Interests - Acceleron Pharma; Agios |
Research Funding - Acceleron Pharma; Agios |
|
|
No Relationships to Disclose |